Condition: Lymphoma, Non-Hodgkin · Relapsed Diffuse Large B Cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma · Sponsor: Abramson Cancer Center at Penn Medicine
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
This description comes directly from the study's public registry record.
Brittany Koch · 215-776-5548 · Brittany.Koch@pennmedicine.upenn.edu
Kaitlin Kennard · Kaitlin.Kennard@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Abramson Cancer Center at the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06458439